AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022
Very low LDL-C Levels Data Reinforces Long-Term Efficacy and Consistent Safety Profile of Repatha Observed in FOURIER-OLE THOUSAND OAKS, Calif., N...
Source: businessinsider.com
Primary Hyperlipidemia News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Primary Hyperlipidemia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Primary Hyperlipidemia Today - Breaking & Trending Today
NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today presented new compelling data from the Phase 3 FOURIER open label extension (OLE) studies of Repatha® (evolocumab) in...
Source: prnewswire.com
NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS - Press Release
Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death80% of Patients Achieved Guideline Directed LDL-C L
Source: wiredprnews.com
AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER...
Source: prnewswire.com
New Data At ESC Congress 2021 Shows Repatha® (evolocumab) Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome (ACS)
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive data from the HUYGENS Phase 3 study showing that Repatha® (evolocumab) in addition to optimized...
Source: prnewswire.com